- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HeartSciences Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | HeartSciences Inc.: HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining | 2 | GlobeNewswire (USA) | ||
| 06.10. | HeartSciences Inc.: HeartSciences Receives FDA 510(k) Clearance for its MyoVista wavECGTM Device | 185 | GlobeNewswire (Europe) | Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing... ► Artikel lesen | |
| 02.10. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.09. | HeartSciences Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 15.09. | Heart Test Laboratories GAAP EPS of -$0.86 misses by $0.11 | 8 | Seeking Alpha | ||
| HEARTSCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.09. | HeartSciences Inc.: HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update | 278 | GlobeNewswire (Europe) | Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026 Commercial effort... ► Artikel lesen | |
| 14.09. | HeartSciences Inc. - 10-Q, Quarterly Report | 7 | SEC Filings | ||
| 25.08. | HeartSciences Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.08. | HeartSciences Inc.: Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration | 364 | GlobeNewswire (Europe) | Fortitude purchased approximately $1,000,000 of HeartSciences' shares of common stock at $2.43 per share, a 22% premium to the closing price on the purchase dateThe exchange ratio under the merger... ► Artikel lesen | |
| 18.08. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | HeartSciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | HeartSciences Inc.: HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results | 312 | GlobeNewswire (Europe) | Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company's shareholders Fiscal 2026 saw the full commercial launch... ► Artikel lesen | |
| 23.07. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | HeartSciences Inc.: HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 23.07. | HeartSciences Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.07. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Fortitude And HeartSciences Announce Business Combination | 1 | pulse2.com | ||
| 23.06. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.06. | Fortitude Mining to merge with HeartSciences in all-stock deal | 2 | Investing.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,920 | -1,17 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer Transition | NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,067 | 0,00 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 0,508 | -12,41 % | Cerenome names Ron Andrews as chief business officer | ||
| ATOSSA THERAPEUTICS | 1,950 | +1,04 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax | Total revenue increased 28% for the quarter and 41% for the six months ended September 30, 2026 compared to same periods last yearU.S. revenue increased 93% for the quarter and 113% for the six months... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | -11,31 % | Tandem Diabetes Care names successor as CEO Sheridan retires | ||
| CO-DIAGNOSTICS | 0,289 | 0,00 % | Co-Diagnostics Reports Third Quarter 2026 Financial Results | Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over YearPlatform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and... ► Artikel lesen | |
| QUIDELORTHO | 10,730 | +3,82 % | QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54B | ||
| VERU | 2,140 | +0,94 % | Veru executive to present obesity drug data at industry conference | ||
| LIFEWARD | 5,840 | +0,52 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,290 | -2,50 % | Clover Health auf der UBS Global Healthcare Conference: Starkes Wachstum trifft auf steigende Ertragskraft | ||
| SENSEONICS | 9,200 | +2,22 % | Senseonics delivers 'breakout quarter' more than doubling Eversense 365 revenue | ||
| TEMPEST THERAPEUTICS | 0,373 | 0,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| NANO-X IMAGING | 0,378 | +1,18 % | Nanox.AI signs distribution deal for cardiac imaging in Thailand | ||
| IMUNON | 0,780 | +13,04 % | IMUNON präsentiert translationale Daten aus Phase-2-Studie bei Eierstockkrebs |
Das Unternehmen HEARTSCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 2,395 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEARTSCIENCES INC finden Sie auf Wallstreet Online.